title: Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
abstract: OBJECTIVE
  The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs.
  
  
  METHODS
  We therefore recruited 60 schizophrenic patients treated with clozapine or other AAPs. We assessed the prevalence rates of OCD or OC symptoms and hypochondriasis or hypochondriac symptoms in the whole group of patients and in clozapine-treated patients versus patients treated with other AAPs.
  
  
  RESULTS
  Schizophrenic patients had a higher comorbidity rate of OCD (26.6% vs 1-3%) and hypochondriasis (20% vs 1%) than the general population. These comorbidities were more frequent in schizophrenic patients treated with clozapine versus patients treated with other AAPs (36.7% vs 16.7% and 33.3% vs 6.7%). Clozapine-treated patients showed a higher mean Y-BOCS and HY-BOCS score when compared to patients treated with other AAPs (10.90 vs 5.90, p = .099; 15.40 vs 8.93, p = .166). A statistical significant correlation was found between the Y-BOCS and HY-BOCS scores of the whole group (r = .378, p = 0.03). Furthermore, we found an inverse correlation between the global level of functioning and the diagnosis of hypochondriasis (p = .048) and the severity of hypochondriac symptoms (p = .047).
  
  
  CONCLUSIONS
  Hypochondriasis could represent an important clinical feature of schizophrenic patients treated with atypical antipsychotics, and further research is needed in this field.
authors.affiliation: 1Department of Neuroscience,University of Florence,AOU Careggi,Florence,Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Grassi
authors.affiliation: 1Department of Neuroscience,University of Florence,AOU Careggi,Florence,Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Poli
authors.affiliation: 1Department of Neuroscience,University of Florence,AOU Careggi,Florence,Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Cantisani
authors.affiliation: 2Department of Molecular and Developmental Medicine,University of Siena,Siena,Italy.
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Righi
authors.affiliation: 1Department of Neuroscience,University of Florence,AOU Careggi,Florence,Italy.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Ferrari
authors.affiliation: 1Department of Neuroscience,University of Florence,AOU Careggi,Florence,Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Pallanti
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D003024:Clozapine / Q000627:therapeutic use; D015897:Comorbidity; D005260:Female; D006801:Humans; D006998:Hypochondriasis / Q000453:epidemiology* / Q000523:psychology; D008297:Male; D008875:Middle Aged; D009771:Obsessive-Compulsive Disorder / Q000453:epidemiology* / Q000523:psychology; D000077152:Olanzapine; D000068882:Paliperidone Palmitate / Q000627:therapeutic use; D015995:Prevalence; D000069348:Quetiapine Fumarate / Q000627:therapeutic use; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D013469:Sulpiride; D000077582:Amisulpride; D000068180:Aripiprazole; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine; D000068882:Paliperidone Palmitate